LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

LifeMD reports robust Q3 results, eyes Medicare expansion for growth

LifeMD's Q3 performance reflects strong revenue growth, operational improvements, and strategic expansion initiatives.
The company's focus on telehealth, men's health, and work simplification businesses is driving positive results.
While facing challenges in scaling operations and market competition, LifeMD is well-positioned for continued growth.
Opportunities in Medicare expansion, program enhancements, and market partnerships offer avenues for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

The company's shares are falling despite stellar preliminary first-quarter revenue results.

Why LifeMD Stock Is Plunging Today

BENSALEM, Pa.--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”). LifeMD investors have until June 15, 2021 to file a lead plaintiff motion. Investors suffering losses on their LifeMD investments are encouraged to contact the Law Offices of Howard G. Smith to discuss

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of LifeMD, Inc. (LFMD) Investors

Exceeds Initial Guidance Due to Stronger Than Expected March; 41% Growth Vs. Q4‘20 Exceeds Initial Guidance Due to Stronger Than Expected March; 41% Growth Vs. Q4‘20

LifeMD Announces Expected Record Revenue of $18.2M for Q1'21, Up 323% Vs. Q1'20, Due to Growth in Subscriptions and Patient Acquisition

LOS ANGELES--(BUSINESS WIRE)---- $LFMD #investors--The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against LifeMD, Inc. (LFMD)

LFMD CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against LifeMD, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Owens v. LifeMD, Inc., et al., (Case No. 1:21-cv-03384) on behalf of persons and entities that purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”). Plaintiff pursues clai

LFMD CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against LifeMD, Inc.

Company cites errors, distortions in anonymous “note” intended to hammer stock for quick profit Company cites errors, distortions in anonymous “note” intended to hammer stock for quick profit

Short-Seller's Note is Short on Credibility, LifeMD Says

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LifeMD, Inc. (NASDAQ: LFMD) on behalf of LifeMD stockholders. Our investigation concerns whether LifeMD has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 14, 2021, Culper Research published a short report alleging that LifeMD, among other things, “ru

LIFEMD ALERT: Bragar Eagel & Squire, P.C. Is Investigating LifeMD, Inc. on Behalf of LifeMD Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your LifeMD investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contac

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of LifeMD, Inc. (LFMD) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors concerning the Company and its officers' possible violations of federal securities laws. On April 14, 2021, Culper Research issued a report alleging that “LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of LifeMD, Inc. (LFMD) on Behalf of Investors

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD) is a leading direct-to-patient telehealth company.

LifeMD Responds to Anonymous Short “Report”

LOS ANGELES--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your LifeMD investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of LifeMD, Inc. (LFMD) on Behalf of Investors

Investors ran for the hills following the release of a short-seller report.

Why LifeMD Stock Is Getting Crushed Today

BENSALEM, Pa.--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of LifeMD (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors concerning the Company's possible violations of federal securities laws. On April 14, 2021, Culper Research issued a report alleging that “LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive telemarketing practice

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of LifeMD (LFMD) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $LFMD #investors--The Law Offices of Frank R. Cruz Announces Investigation of LifeMD, Inc. (LFMD) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of LifeMD, Inc. (LFMD) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - April 14, 2021) - Holzer & Holzer, LLC is investigating whether LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") complied with federal securities laws. On April 14, 2021, Culper Research published a short report alleging that LifeMD, among other things, "runs afoul of numerous FTC regulations". The price of LifeMD shares plummeted following the report.If you purchased shares of LifeMD and suffered a loss on that investment,...

SHAREHOLDER ALERT: Investigation of LifeMD, Inc. Announced by Holzer & Holzer, LLC

The stock price of LifeMD Inc (NASDAQ: LFMD) fell by over 20% during intraday trading. This is why it happened.

LFMD Stock: Over 20% Decrease Intraday Explanation

Revenue is accelerating and the company's platform is almost endlessly leverageable with new brands and products. However, as the company is still in the land-grab phase, investments are accelerating even more steeply, and one could argue, worryingly.

Land Grab At LifeMD

The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare

LifeMD Launches NavaMD™ Adding Direct-to-Patient Clinical Skincare Services to its Portfolio of Personalized Telehealth Brands

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q4 2020 Results - Earnings Call Transcript

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and full year ended December 31, 2020. All quarterly and full year comparisons are to the same year-ago period. The company will hold a conference call at 4:30 p.m. Eastern time today to discuss the results (see dial-in information below.)

LifeMD Reports Q4 2020 Revenue up 227% to Record $12.9 Million, Full Year up 199% to Record $37.3 Million

NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will hold a conference call on Monday, March 29, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. The financial results will be issued in a press release prior to the call.

LifeMD to Host Fourth Quarter and Full Year 2020 Conference Call on Monday, March 29, 2021 at 4:30 p.m. ET

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc.  (NASDAQ: LFMD), a leading direct-to-patient telehealth company, announced that the Compensation Committee of the Company's Board of Directors granted an equity award to a new employee with a grant date of March 15, 2021, as an equity inducement award outside of the Company's 2020 Equity and Incentive Plan (but under the terms of the 2020 Equity and Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on March 15, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

LifeMD Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, has been invited to participate at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.

LifeMD to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- LifeMD , Inc. (NASDAQ: LFMD) (formerly Conversion Labs), a leading direct-to-patient telehealth company, expects revenue for the first quarter ending March 31, 2021 to exceed $17 million, up more than 295% compared to the same year-ago quarter.

LifeMD Q1 2021 Revenues on Track to Exceed $17 Million, up 295%, with Subscriptions Representing More than 80% of Total Revenue

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock's new CUSIP number will be 53216B 104.

News for LifeMD Stock (LFMD)